Calendar
Highlights of ASH®
Get a synopsis of the top hematology research
presented at the 2015 ASH Annual Meeting and learn
how it can help improve your patient management and
care strategies. This is an opportunity to evaluate your
diagnostic techniques and therapeutic approaches and
discuss with leading hematology experts and colleagues
how new research and clinical updates can be translated
into patient care strategies.
April 28, 2016–May 1, 2016
June 9–12, 2016
Oncology Nursing Society Annual Congress
European Hematology Association Annual
Congress
San Antonio, Texas
This year’s Annual Congress will feature the latest
developments in oncology nursing and patient care,
as well as networking opportunities for the more than
3,000 attendees.
Copenhagen, Denmark
The 21st Annual Congress will provide a forum for sharing clinical and translational research in hematologic
disorders and disseminating evidence-based knowledge.
March 5–6, 2016
Brisbane, Australia
April 29–30, 2016
Natal, Brazil
Nyhavn harbour in Copenhagen
March 9–12, 2016
American Academy of Hospice and
Palliative Medicine Annual Assembly
Chicago, Illinois
This educational event brings together physicians,
nurses, and other health-care providers to share
research, clinical best practices, and practice-related
guidance to improve quality of life for patients and
families facing serious or life-threatening conditions.
When Treating Acquired Hemophilia A
PROCEED WITH CONFIDENCE
ABOUT
The first recombinant
porcine sequence factor VIII
replacement treatment1
RESPONSE
Fast-acting: 95% (19/20)
response seen at 8 h; 100%
(18/18) at 16 h; 100% (28/28)
at 24 h after initial dosing1
EFFICACY
94% (16/17) of patients
treated first-line achieved
overall treatment success1
SAFETY
Safety profile established in the
adult population in a clinical trial1
MEASURABILITY
The ability to measure factor VIII levels
helps find the right dosing balance1
Statue of Abraham Lincoln in Chicago, Illinois
March 31–April 2, 2016
National Comprehensive Cancer
Network Annual Conference
Hollywood, Florida
The theme of this year’s NCCN Annual Conference
is “Advancing the Standard of Cancer Care.” Attendees will discuss the latest cancer therapies,
quality initiatives, and selected NCCN Clinical
Practice Guidelines in Oncology.
The efficacy (N=28) and safety (N=29) of OBIZUR were studied
in the first interventional, prospective, clinical trial for acquired
hemophilia A (AHA) patients. Patients were treated with OBIZUR
until resolution of bleeding, or dosing was continued at the
physician’s discretion according to the clinical assessment.1
Indication
OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is
a recombinant DNA derived, antihemophilic factor indicated for the
treatment of bleeding episodes in adults with acquired hemophilia A.
Limitations of Use:
April 16–20, 2016
American Association of Cancer
Research Annual Meeting
New Orleans, Louisiana
The AACR Annual Meeting will highlight the latest
discoveries in every area of cancer research, from
molecular biology to clinical studies, epidemiology, prevention, and survivorship.
April 18–21, 2016
International Society of Hematology’s
36th World Congress
Glasgow, Scotland, UK
The 36th World Congress, hosted by the British
Society of Hematology, gathers international
members of the hematology community to
network and discuss the changing clinical and
laboratory practice landscape, as well as report on
advances in the field.
ASHClinicalNews.org
• Safety and efficacy of OBIZUR has not been established
in patients with baseline anti-porcine factor VIII inhibitor
titer greater than 20 BU
• OBIZUR is not indicated for the treatment of congenital
hemophilia A or von Willebrand disease
Detailed Important Risk Information
CONTRAINDICATIONS
OBIZUR is contraindicated in patients who have had life-threatening
hypersensitivity reactions to OBIZUR or its components (including
traces of hamster proteins).
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions can occur with OBIZUR. OBIZUR
contains trace amounts of hamster proteins. Early signs
of allergic reactions, which can progress to anaphylaxis,
include angioedema, chest-tightness, dyspnea, hypotension,
wheezing, urticaria, and pruritus. Immediately discontinue
administration and initiate appropriate treatment if allergic
or anaphylactic-type reactions occur.
Visit www.OBIZUR.com
If the plasma factor VIII level fails to increase as expected, or if
bleeding is not controlled after OBIZUR administration, suspect the
presence of an anti-porcine factor VIII antibody. If such inhibitory
antibodies to anti-porcine factor VIII are suspected and there is a
lack of clinical response, consider other therapeutic options.
Monitoring Laboratory Tests
• Perform one-stage clotting assay to confirm that adequate
factor VIII levels have been achieved and maintained
- Monitor factor VIII activity 30 minutes and 3 hours after
initial dose
- Mon